AstraZeneca PLC — Regulatory Filings 2016

Nov 1, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of November 2016

Commission File Number: 001-11960

AstraZeneca PLC

1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_______

AstraZeneca PLC

INDEX TO EXHIBITS

1.

Dealing by Person Closely Associated dated 01 st November 2016

1 November 2016 15:30

Transaction by Person Closely Associated with a Person Discharging Managerial Responsibilities

Disclosure under Articles 19(3) and 19(6) of the EU Market Abuse Regulation

On 31 October 2016, Mrs Susan Chipchase notified us that, on 27 October 2016, she purchased 100 AstraZeneca PLC Ordinary Shares of US$0.25 each at a price of £48.08 per share.

Mrs Chipchase is a person closely associated with Graham Chipchase, a Non-Executive Director of AstraZeneca PLC.

The attached notification, made in accordance with the requirements of the EU Market Abuse Regulation, gives further detail.

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

| 1 — a) | Details of the person discharging managerial responsibilities /
person closely associated — Name | Susan
Chipchase | |
| --- | --- | --- | --- |
| 2 | Reason for the notification | | |
| a) | Position/status | Person
Closely Associated with a Person Discharging Managerial
Responsibilities (PDMR) in respect of AstraZeneca PLC | |
| b) | Initial
notification /Amendment | Initial
notification | |
| 3 | Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor | | |
| a) | Name | AstraZeneca
PLC | |
| b) | LEI | Not
applicable | |
| 4 | Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transactions have been
conducted | | |
| a) | Description
of the financial instrument, type of instrument Identification
code | Ordinary
Shares of US$0.25 each in AstraZeneca PLC GB0009895292 | |
| b) | Nature
of the transaction | Acquisition | |
| c) | Price(s)
and volume(s) | Price(s) | Volume(s) |
| | | 4807.95
pence | 100 |
| d) | Aggregated
information -
Aggregated volume -
Price | Not
applicable - single transaction | |
| e) | Date of
the transaction | 27
October 2016 | |
| f) | Place
of the transaction | London | |

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

| Media Enquiries — Neil
Burrows | UK/Global | +44 203
749 5637 |
| --- | --- | --- |
| Vanessa
Rhodes | UK/Global | +44 203
749 5736 |
| Karen
Birmingham | UK/Global | +44 203
749 5634 |
| Rob
Skelding | UK/Global | +44 203
749 5821 |
| Jacob
Lund | Sweden | +46 8
553 260 20 |
| Michele
Meixell | US | +1 302
885 2677 |
| Investor Relations | | |
| Thomas
Kudsk Larsen | | +44 203
749 5712 |
| Craig
Marks | Finance,
Fixed Income, M&A | +44
7881 615 764 |
| Henry
Wheeler | Oncology | +44 203
749 5797 |
| Mitchell
Chan | Oncology | +1 240
477 3771 |
| Lindsey
Trickett | Cardiovascular
& Metabolic Diseases | +1 240
543 7970 |
| Nick
Stone | Respiratory | +44 203
749 5716 |
| Christer
Gruvris | Autoimmunity,
neuroscience & infection | +44 203
749 5711 |
| US toll
free | | +1 866
381 7277 |

Adrian Kemp

Company Secretary, AstraZeneca PLC

-ENDS-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AstraZeneca PLC

| Date:
01 November 2016 |
| --- |
| Name:
Adrian Kemp |
| Title:
Company Secretary |

page break